Table 2

Reasons for SRI(4) response at week 52 in TULIP-1 among BICLA non-responders/SRI(4) responders

SLEDAI-2K domain, n (%)BICLA non-responders/SRI(4) responder in TULIP-1
Placebo
(n=28)
Anifrolumab 300 mg
(n=12)
Arthritis22 (78.6)6 (50.0)
 Arthritis only7 (25.0)0
 Arthritis+other items15 (53.6)6 (50.0)
Rash1 (3.6)2 (16.7)
 Rash+other items1 (3.6)2 (16.7)
Proteinuria2 (7.1)2 (16.7)
 Proteinuria only1 (3.6)0
 Proteinuria+other items1 (3.6)2 (16.7)
Mucosal ulcers+anti-dsDNA01 (8.3)
Mucosal ulcers+low complement1 (3.6)0
Alopecia+low complement+leucopenia01 (8.3)
Vasculitis+low complement1 (3.6)0
Anti-dsDNA antibodies+low complement1 (3.6)0
  • anti-dsDNA, anti-double-stranded DNA; BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SRI(4), Systemic Lupus Erythematosus Responder Index of ≥4.